BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Lymphoma Treatment Shows Promise


10/19/2005 5:12:37 PM

A one-time treatment that uses a homing-device drug to zap cancer cells with radiation made a deadly lymphoma disappear in three out of four patients, many for nearly eight years, researchers report. While the results were called promising, it's not known yet whether the novel approach will be superior to the standard early treatments normally used for a slow-growing but incurable type of non-Hodgkin's lymphoma. "The striking thing about it is how such a short treatment can produce such long-lasting remissions," said Dr. Mark S. Kaminski, who developed the new treatment, Bexxar, with a University of Michigan colleague. The researchers said more studies will be needed to determine whether doctors should use Bexxar as a first treatment to fight the immune-system cancer. Bexxar is only approved for use when other therapies, including chemotherapy and radiation, fail. Bexxar treatment starts with a test dose followed by a full dose a week later instead of over months, as with chemotherapy. One advantage is fewer side effects, such as hair loss, the researchers said. The findings reported in Thursday's New England Journal of Medicine (news - web sites) were partly funded by drug maker Corixa, which recently sold the rights to Bexxar to GlaxoSmithKline. Some of the scientists have received fees from the drug makers; one was a Corixa employee. The university holds patents for Bexxar, and Kaminski and his co-inventor share in royalties.

Read at Reuters
Read at AP
Read at HealthDay
Read at WebMD
Read at Health Talk

Reuters
AP
HealthDay
WebMD
Health Talk
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES